New research on the COX-2 pathway indicates that it might be possible for COX-2 drugs to achieve anti-inflammatory protection, without the cardiovascular risk, by developing drugs that target another enzyme. 

, a new study used genetically altered mice to analyze the physiological reasons for the dangerous cardiovascular side effects associated with COX-2 drugs.

The results show that COX-2 inhibitors promote heart disease by suppressing production of a fat called prostacyclin, explained lead author Garret FitzGerald.

When the receptor for prostacyclin was genetically removed from mice, the cardiovascular effects were the same as those caused by COX-2 drugs.

Prostacyclin is one of several molecules produced by COX-2 that cause pain and inflammation, FitzGerald elaborated.

But it also protects the heart by preventing blood clots, resisting artery hardening, and helping maintain balanced blood pressure.

FitzGerald's research investigated another target for anti-inflammatory drugs. Prostaglandin E2, also produced in the COX-2 pathway, has mixed effects, he said. 

Prostaglandin E2 is made by an enzyme called microsomal PGE synthase-1. When microsomal PGE synthase-1 is suppressed the precursor to prostaglandin E2 is converted into prostacyclin instead.

This could mean that drugs targeting microsomal PGE synthase-1 would increase levels of prostacyclin, the opposite effect of COX-2 drugs, FitzGerald indicated. But it would probably decrease levels of prostaglandin E2.

Previous research has shown that eliminating the ability to produce microsomal PGE synthase-1 is still effective at fighting inflammation, he added.

FitzGerald believes more research is needed to understand whether drugs targeting microsomal PGE synthase-1would be effective in people.

Another product of COX-2, thromboxane, has negative effects on the heart, according to FitzGerald. But COX-2 drugs do not alter thromboxane levels.

The National Institutes of Health and Merck funded this research. Merck manufactured Vioxx (rofecoxib), a COX-2 that was pulled from the market for its cardiovascular side effects.

Articles

A new study details the physiological reasons why COX-2 inhibitorsincrease the risk of heart disease. Suppressing the production of one key fact does reduce pain, but it also deprives the body of a mechanism to curb blood clots, resist artery hardening, and regulate blood pressure.

Why COX-2 Inhibitors Hurt the Heart

) has signed a distribution agreement with 

). The deal gives Cytogen exclusive US marketing rights to 

 (tamoxifen citrate), a hormone therapy for cancer. Soltamox is a liquid product taken orally. That offers a strong potential advantage to the roughly 40 percent of adults who have difficulty swallowing pills. Soltamox is the first liquid oral hormonal anti-cancer drug to be approved in the United States. Under the deal, Savient receives $2 million up front, plus milestone payments of $4 million and royalties.

) has acquired the US rights to manufacture and commercialize 

). The drug is an anti-protozoal, primarily used to treat trichomoniasis, a sexually transmitted parasitic disease that affects 7.4 million people a year. It is also indicated for giardiasis, intestinal amebiasis, and amebic liver abscess. 

) has announced that it has signed a licensing agreement giving 

) exclusive rights to manufacture, develop, and commercialize one of its drug candidates. The product, currently in preclinical studies, inhibits the action of the enzyme MAPK/ ERK kinase (MEK), which plays a role in cell proliferation. MEK inhibition may be useful in treating cancer and inflammation. Japan Tobacco retains Japanese co-promotion rights. Japan Tobacco is the world’s third-largest tobacco company, with $39 billion in sales, but also has a pharmaceutical business with sales of about $500 million. Terms of the deal were not disclosed.

) have signed an agreement to jointly research, develop, and commercialize a broad range of therapies for eye diseases. Under the agreement, Amgen will provide candidate molecules and Alcon will lead clinical development and commercialization. Amgen will license Alcon ophthalmic use of any products developed by the partnership, but will retain rights to other indications.

) has made a two-year research and license agreement with 

). The multi-product deal, potentially worth more than $75 million, will cover novel therapeutics for rheumatoid arthritis and other diseases. Five Prime will receive an upfront fee, research support, milestone payments, and royalties. Boehringer Ingelheim will have exclusive worldwide development and commercialization rights. Five Prime was founded in 2002 by Lewis T. “Rusty” Williams, former chief scientific officer for 

. The company specializes in research into the human “secretome,” the set of proteins from which biotherapeutics are derived.

) to develop treatments for infectious diseases. Elusys is a privately company that develops anti-infectives based on its heteropolymer antibody technology. According to the company, the technology uses a monoclonal antibody specific to a red blood cell receptor. This receptor is chemically linked to a second antibody that binds a particular pathogen. The deal includes an undisclosed upfront payment to Elusys, milestones, and royalties. In addition, MedImmune’s venture capital unit will make an investment in Elusys.

During the past two weeks, companies from a half dozen states and three foreign lands joined forces. Here?s an update on who?s working with whom.

Pharmaceutical Executive-04-26-2006

Why COX-2 Inhibitors Hurt the Heart

New Licensing and Development Agreements